Douglas F Kling sold $1.9M of NAMS
Chief Operating Officer at NewAmsterdam Pharma Co N.V.. 100,000 shares at an average of $19.29, traded Jun 16, 2025, filed Jun 18, 2025.
Score components
- +20RoleCOO
- +25Trade size$1.9M at market
- +20Share of holdings soldSold 69% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-087937, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 16, 2025 | MOption exercise Ordinary Shares10b5-1 | +78,101 | $10.00 | $781k | 122,101 | Jun 18, 2025 |
| Jun 16, 2025 | MOption exercise Ordinary Shares10b5-1 | +21,899 | $10.90 | $239k | 144,000 | Jun 18, 2025 |
| Jun 16, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -81,891 | $19.19 | $1.6M | 62,109 | Jun 18, 2025 |
| Jun 16, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -18,109 | $19.75 | $358k | 44,000 | Jun 18, 2025 |
| Jun 16, 2025 | MOption exercise Option (right to buy)derivative10b5-1 | -78,101 | $0.00 | $0 | 372,829 | Jun 18, 2025 |
| Jun 16, 2025 | MOption exercise Option (right to buy)derivative10b5-1 | -21,899 | $0.00 | $0 | 261,314 | Jun 18, 2025 |
Related signals
Other insiders at NewAmsterdam Pharma Co N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $1.3M 50,246 shares | -42% | |
| 38Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | Michael H. Davidson Chief Executive Officer | $227k 10,000 shares | +1% | |
| 26Weak | NAMSsell NewAmsterdam Pharma Co N.V. | John W Smither director | $41k 1,600 shares | -15% | |
| 25Weak | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $5.2M 145,000 shares | -161% | |
| 15Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | James N Topper director | $16k 660 shares | +0% | |
| 45Moderate | NAMSsell NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $3.9M 150,000 shares | -91% | |
| 20Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | James N Topper director | $31k 1,260 shares | +0% | |
| 60Notable | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $453k 18,073 shares | -55% | |
| 45Moderate | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $206k 8,269 shares | -36% | |
| 68Notable | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $2.5M 100,000 shares | -59% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.